NASDAQ:PPH VanEck Pharmaceutical ETF (PPH) Price, Holdings, & News $90.42 -0.11 (-0.12%) Closing price 06/11/2025 03:59 PM EasternExtended Trading$90.42 0.00 (0.00%) As of 04:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock About VanEck Pharmaceutical ETF (NASDAQ:PPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PPH alerts:Sign Up Key Stats Today's Range$90.18▼$91.0650-Day Range$80.28▼$90.5352-Week Range$77.67▼$99.51Volume316,005 shsAverage Volume257,270 shsMarket Capitalization$564.22 millionAssets Under Management$578.07 millionDividend Yield1.88%Net Expense Ratio0.36%Aggregate RatingModerate Buy ETF OverviewThe VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.Read More… VanEck Pharmaceutical ETF ExpensesTypePPHHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.35%0.57%0.57%0.54%0.54%Other Expenses0.01%0.30%0.48%0.42%0.51%Total Expense0.36%0.70%0.72%0.69%0.71%Fee Waiver0.00%-0.45%-0.49%-0.29%-0.54%Net Expense0.36%0.61%0.63%0.62%0.60% Receive PPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VanEck Pharmaceutical ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address PPH ETF News HeadlinesPPH, Big Pharma Stocks Volatile on Trump Drug PricingMay 14, 2025 | finance.yahoo.comPPH: Will Overcome Tariffs, But Competitor Funds Look StrongerApril 14, 2025 | seekingalpha.comTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...June 12, 2025 | InvestorPlace (Ad)Big Pharma higher after tariff exemption despite ongoing uncertaintiesApril 3, 2025 | msn.comVanEck Vectors Pharmaceutical ETF declares quarterly distribution of $0.4110December 27, 2024 | msn.comThe Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, PPH, HRTS and THNROctober 17, 2024 | finance.yahoo.comSee More Headlines PPH ETF - Frequently Asked Questions How have PPH shares performed this year? VanEck Pharmaceutical ETF's stock was trading at $86.28 at the start of the year. Since then, PPH stock has increased by 4.8% and is now trading at $90.42. View the best growth stocks for 2025 here. Who are VanEck Pharmaceutical ETF's major shareholders? VanEck Pharmaceutical ETF's top institutional shareholders include Goldman Sachs Group Inc. (16.14%), Avalon Trust Co (3.95%), J.Safra Asset Management Corp (3.59%) and Miller Investment Management LP (2.64%). How do I buy shares of VanEck Pharmaceutical ETF? Shares of PPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of VanEck Pharmaceutical ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that VanEck Pharmaceutical ETF investors own include Waste Connections (WCN), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), American Water Works (AWK) and Triple Flag Precious Metals (TFPM). Fund Details IssuerVan Eck Fund NameVanEck Pharmaceutical ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:PPH Inception Date12/20/2011 Fund ManagerHao-Hung Peter Liao, Guo Hua Jason Jin WebN/A Phone14089961010Fund Focus Asset ClassEquity BenchmarkMVIS US Listed Pharmaceutical 25 Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionGlobal Number of Holdings25 Fund Statistics Assets Under Management$578.07 million Average Daily Volume$520.49 thousand Discount/Premium0.04% Administrator, Advisor and Custodian AdministratorVan Eck Associates Corporation AdvisorVan Eck Associates Corporation CustodianState Street Bank and Trust Company DistributorVan Eck Securities Corporation Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerIMC Options OptionableOptionable Options Volume304 Put Options224 Call Options80 Short Interest2,570,000 shs Miscellaneous Outstanding Shares6,240,000Beta0.55 Creation Unit50,000 Creation Fee$500.00 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Top 10 PPH HoldingsEli Lilly and Company (NYSE:LLY)Holding Weight: 11.44%Johnson & Johnson (NYSE:JNJ)Holding Weight: 6.41%AbbVie (NYSE:ABBV)Holding Weight: 6.18%Novartis AG ADRHolding Weight: 5.65%Cencora (NYSE:COR)Holding Weight: 5.33%McKesson (NYSE:MCK)Holding Weight: 5.21%Haleon (NYSE:HLN)Holding Weight: 5.12%Novo Nordisk A/S (NYSE:NVO)Holding Weight: 5.06%AstraZeneca (NASDAQ:AZN)Holding Weight: 4.99%GSK (NYSE:GSK)Holding Weight: 4.96%Full Holdings DetailsPPH Sector ExposurePPH Industry Exposure This page (NASDAQ:PPH) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VanEck Pharmaceutical ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share VanEck Pharmaceutical ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
